Implementation of CAR-T cell therapy in outpatient settings: a critical review of current literature regarding health outcomes, benefits, challenges, and future directions.

This review article examines the emerging practice of delivering CAR T‑cell therapy for hematologic malignancies in the outpatient setting.

Key points:

• Rationale and trend: While CAR T‑cell therapy has historically been given inpatient due to acute toxicities, there is increasing movement toward outpatient administration in appropriately selected patients.

• Patient selection and feasibility: With strict selection criteria, structured pathways, and strong institutional infrastructure, outpatient programs can achieve similar efficacy and safety to inpatient care. Success hinges on:

• • Clear eligibility criteria (clinical stability, proximity to center, reliable caregiver support).
• • Standardized monitoring protocols and rapid re-admission pathways.

• Toxicity focus – CRS and ICANS: The review highlights Cytokine Release Syndrome (CRS) and Immune Effector Cell–Associated Neurotoxicity Syndrome (ICANS) as the main barriers to outpatient care. It emphasizes the need for:

• • Early recognition algorithms,
• • Education of patients/caregivers on red-flag symptoms,
• • Ready access to urgent evaluation and treatment (e.g., tocilizumab, corticosteroids, ICU support if needed).

• Benefits of outpatient administration:

• • Health system impact: Reduced inpatient bed utilization and overall costs; better allocation of hospital resources.
• • Patient-centered outcomes: Enhanced psychological well-being, greater sense of normalcy, and less disruption to daily life.

• Limitations and risks: Outpatient programs require:

• • Specialized multidisciplinary teams with CAR-T expertise,
• • Continuous or near-continuous monitoring capacity,
• • Reliable systems to ensure rapid escalation of care.
• Concerns about equitable access, especially for patients living far from treatment centers or with limited support systems.

• Future directions: Advances in CAR-T design (e.g., improved safety profiles, more predictable toxicity) and remote monitoring technologies (e.g., telehealth, wearable devices) are identified as crucial to broadening safe outpatient use. The authors suggest that, with these developments and carefully structured care models, outpatient CAR T‑cell therapy is poised to become a more widely adopted standard of care.